ClinicalTrials.gg
RecruitingNCT06798077CAM CohortUpdated Feb 17, 2025

Chronic Airway Disease and Multimorbidity Cohort

An observational study in Chronic Obstructive Pulmonary Disease (COPD), Asthma and Bronchiectasis, sponsored by China-Japan Friendship Hospital. Recruiting at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by China-Japan Friendship Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital — 16 open to participants now, 17 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · China-Japan Friendship Hospital.

Planned enrollment
5th of 11
2,000 · median 1,500
Started
2025
with 1 other
Observational
11 of 24
7 open now
Primary completion
2028-07
later than 14 of 16 live
Registered
21st of 24
by date

Among the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, reaches primary completion later than 14 of the 16 other live ones, and was the 21st registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

16 of the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, or all of them as a file.
02

Study summary

Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated.

Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will be collected at 1-, 3-, 6-, 9- and 12-months after hospital discharge. Biospecimens, including blood and bronchoalveolar lavage fluid, will be collected and analyzed for biomarker detecting. Primary outcome are length of hospital stay and re-exacerbation during fellow-up. Secondary outcomes include comorbidity pattern and its impact on respiratory symptoms burden, quality of life, pulmonary function and chest imaging as well as cost and healthcare utilization.

Conclusions: The knowledge generated from CAM cohort study will fill crucial gaps in understanding how multimorbidity affects CAD and facilitate evidence-based clinical practice in the future.

Read the detailed description

The Chronic Airway Disease and Multimorbidity (CAM) Cohort is a nationwide, prospective, multicenter, longitudinal observational study aimed at understanding the epidemiology and impact of multimorbidity on patients hospitalized due to exacerbation of chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis. The study will enroll 2,000 patients across 9 medical centers in China, following their health trajectory for one year post-hospitalization.

Objective The primary objective is to assess how multimorbidity influences treatment outcomes, hospitalization length, and readmission rates in CAD patients. Secondary goals include analyzing comorbidity patterns, their effects on symptom burden, quality of life, pulmonary function, healthcare costs, and utilization.

Study Design Participants meeting inclusion criteria will be recruited through hospital advertisements and professional referrals. Upon providing informed consent, demographic, clinical, and laboratory data will be recorded during baseline hospitalization. The study employs standardized questionnaires and clinical tools such as mMRC, CAT, and SGRQ for quality-of-life assessments. Specimens, including blood, bronchoalveolar lavage fluid (BALF), and sputum, will be collected and stored for biomarker analysis. Imaging studies such as chest CT and echocardiography will evaluate disease severity and cardiac function.

Patients will be systematically followed at 1, 3, 6, 9, and 12 months post-discharge to record disease progression, treatment adherence, exacerbations, and outcomes.

Data Collection Demographics and Risk Factors: Age, gender, smoking history, family history, and occupational exposures.

Symptoms: Disease-specific tools such as CAT/mMRC(COPD), ACQ-7 (asthma) and BEST (bronchiectasis) will quantify symptom severity.

Quality of Life (QoL): SGRQ for COPD, QoL-Bronchiectasis for bronchiectasis, and mini-AQLQ for asthma patients.

Laboratory Data: Arterial blood gas, blood count, liver and renal function, inflammatory markers, and allergy panels.

Muti-morbidities: Systematic documentation of pulmonary and extrapulmonary comorbidities, including their diagnosis, treatment, and severity.

Outcome Measures: The primary outcomes are hospital length of stay and re-exacerbation rates. Secondary outcomes include changes in pulmonary function, QoL, mental health indices, imaging findings, and healthcare resource utilization.

Quality Control Data will be managed using an electronic data capture(EDC) system, with built-in validation to ensure accuracy. Periodic data audits and centralized training for research coordinators will enhance data integrity. Monitoring committees will address data discrepancies promptly.

Ethics and Dissemination The protocol complies with the Declaration of Helsinki and has received approval from ethics committees of all participating centers. The findings will inform clinical guidelines, emphasizing the integration of multi-morbidity management in CAD care.

This study bridges significant knowledge gaps in CAD management, particularly concerning multimorbidity in hospitalized patients, aiming to enhance evidence-based clinical practices.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Bronchiectasis

Keywords

  • multimorbidity
  • COPD
  • asthma
  • bronchiectasis
  • exacerbation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The CAM cohort study focuses on hospitalized patients with chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis, during acute exacerbation episodes. Participants are recruited from 9 medical centers across China, representing diverse geographic and clinical settings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age;
  • The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis".

Exclusion criteria

Exclusion Criteria:

  • Patients were unable to undergo spirometry during the stabilization period;
  • Expected survival is less than 1 month;
  • Refusal to sign an form;
  • Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion;
  • Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • COPD group
  • Asthma Group
  • Bronchiectasis Group
06

What researchers measure

Primary outcomes

  1. Length of hospital stay

    The length of time participants remain hospitalized from the date of admission to the date of discharge or death, whichever comes first.

    Time frame: From the date of admission until discharge or death, assessed over an estimated period of 3 to 30 days.

Secondary outcomes

  1. Acute exacerbation during follow-up

    Exacerbations will be defined based on clinical criteria specific to each disease: increased respiratory symptoms requiring additional treatment. Measurement Tools: The number of disease exacerbation.

    Time frame: From the date of discharge to 12 months post-discharge.

  2. All cause mortality

    All cause mortality.

    Time frame: In-hospital and from enrollment to 12 months.

  3. Quality of Life in COPD Patients

    Assessing quality of life in patients with COPD using validated tools. Measurement Tools: St. George's Respiratory Questionnaire (SGRQ), scores range from 0 to 100, with higher scores indicating worse quality of life.

    Time frame: From enrollment to 12 months.

  4. Quality of Life in Asthma Patients

    Assessing quality of life in patients with asthma using validated tools. Measurement tool: Mini Asthma Quality of Life Questionnaire (Mini-AQLQ), each question is scored from 1 to 7, with 15 questions and a total score of 105. The higher the score, the better the quality of life.

    Time frame: From enrollment to 12 months

  5. Quality of Life in Bronchiectasis Patients

    Assessing quality of life in patients with bronchiectasis using validated tools. Measurement tool: Bronchiectasis Health Questionnaire (BHQ), each question is scored from 1 to 7, with 10 questions and a total score of 70. The higher the score, the better the quality of life.

    Time frame: From enrollment to 12 months.

  6. Lung Function

    Assessment of lung function (FEV 1) over time.

    Time frame: From enrollment to 12 months

  7. Healthcare Costs

    Evaluation of total healthcare costs related to the treatment of CAD, including direct costs such as hospitalisation, medication and outpatient costs. Measurement Unit: Total cost in local currency (e.g., RMB).

    Time frame: In-hospital and from enrollment to 12 months.

  8. Adherence to Prescribed Medications and Treatments

    Evaluation of participants' adherence to prescribed medication regimens and treatments, using patient-reported adherence and prescription records. Measurement Unit: Percentage of adherence (e.g., percentage of days covered).

    Time frame: From enrollment to 12 months.

  9. Polypharmacy Patterns

    Analysis of the prevalence and patterns of polypharmacy, defined as the use of 2 or more medications concurrently. Measurement Unit: Number of concurrent medications.

    Time frame: From enrollment to 12 months.

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The CAM cohort study has determined that individual participant data (IPD) will not be directly shared. Instead, supporting information and aggregated results will be made available in specific formats to ensure transparency while protecting participant privacy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2028, 41 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 41 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 29, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06798077
Collaborators
Second Affiliated Hospital of Xi'an Jiaotong University, First Hospital of China Medical University, Henan Provincial People's Hospital, Second Xiangya Hospital of Central South University, Sichuan University, Southern Medical University, China, Ruijin Hospital, Wuhan Union Hospital, China
Responsible party
Ting YANG (Professor, China-Japan Friendship Hospital) — Principal investigator
First posted
Jan 29, 2025
Start date
Feb 1, 2025
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Feb 17, 2025

Study contacts

Ke Huang, MD.
Contact
huangke_zryy@163.com
+8615120079197
Wei Li, MD.
Contact
412633088@qq.com
+8615910971249
Ting Yang, MD
principal investigator · China-Japan Friendship Hospital, National Center for Respiratory Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion